Comparative Pharmacology
Head-to-head clinical analysis: AMTURNIDE versus LOPRESSIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMTURNIDE versus LOPRESSIDONE.
AMTURNIDE vs LOPRESSIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Lopressidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2, and also blocks alpha1-adrenergic and H1 histamine receptors.
10 mg to 20 mg orally once daily, with or without food.
Oral: 5 mg twice daily, titrate as tolerated up to 20 mg twice daily. Maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
12-15 hours; allows once-daily dosing, but steady-state reached in ~3-5 days.
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal: ~60% (as unchanged drug); Fecal: ~30% (as metabolites); Biliary: minor (<5%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination